



BMS-819881

Catalog No: tcsc0011370

Z	Available Sizes
Size:	1mg
Size:	5mg
Size:	10mg
	Specifications
CAS N 11974	lo: 20-05-5
Formu	ula: 1 ^{CIN} 2 ^O 4 ^S
Pathw Metab	vay: olic Enzyme/Protease;GPCR/G Protein
Targe Cytoch	rt: nrome P450;MCHR1 (GPR24)
Purity / Grade: >98%	
Solub 10 mM	ility: 1 in DMSO
Obser 468.95	ved Molecular Weight:

Product Description

BMS-819881 is a melaninconcentrating hormone receptor 1 (MCHR1) antagonist, which binds rat MCHR1 with a $\mathbf{K_i}$ of 7 nM. BMS-819881 also is selective and potent for CYP3A4 activity with an $\mathbf{EC_{50}}$ of 13 μ M.





IC50 & Target: Ki: 7 nM (rat MCHR1)^[1]

EC50: 13 μ M (CYP3A4)^[1]

In Vitro: BMS-819881 (Compound 27) is 99.8% binds to rat serum proteins and rat MCHR1 K_i is 7 nM. FLIPR-based assays establish that BMS-819881 is a potent and highly selective MCHR1 functional antagonist. BMS-819881 (K_b =32 nM) effectively blocks MCH stimulated Ca²⁺ mobilization in heterologous cells overexpressing MCHR1 but fails to inhibit MCH mediated Ca²⁺ mobilization of cells expressing MCHR2 at 10 μ M. No activity is observed upon screening BMS-819881 at 10 μ M versus a panel of 20 GPCRs associated with feeding homeostasis. The percent of BMS-819881 binds to serum proteins is species dependent ranging from 99.8%, 99.6%, and 99.3%, respectively, for rat, dog, and monkey. When BMS-819881 is screened for cytochrome P450 (CYP) activity, EC₅₀ values for CYP1A2, CYP2C9, CYP2C19, CYP2D6 are >40 μ M; however, the CYP3A4 EC₅₀ is 13 μ M^[1].

In Vivo: BMS-819881 has moderate terminal elimination half-life ($t_{1/2}$ =5.7 h, 32±8 h, and 14±3 h for rat (1 mg/kg, iv), dog (1 mg/kg, iv), and cynomologous monkey (1 mg/kg, iv))^[1].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!